Tumor Activity Manufacturers, Suppliers & Companies
-
Manufacturerbased in Redmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...
SystImmune - Model SI-B003 - Tetravalent
upon treatment with PD-1 and CTLA-4 blocking antibodies, restoring their anti-tumor activity. SI-B003 is currently being evaluated as a single agent in clinical trials enrolling patients with a variety of solid ...
CONTACT SUPPLIER -
Manufacturerbased in Berlin, GERMANY
T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer. The company is initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a promising modality that holds the ...
-
Manufacturerbased in Cambridge, MASSACHUSETTS (USA)
Mersana is a biopharmaceutical company specializing in the discovery and development of antibody-drug conjugate (ADC) therapies to treat patients fighting cancer. Leveraging decades of industry learnings, we have developed proprietary and highly ...
Model STING-Agonist - Immunosynthen
of efficacy, delivery and tolerability. Stimulator of Interferon Genes (STING) is a well-studied innate immune pathway capable of inducing anti-tumor immune activity. Our preclinical data show that the ...
CONTACT SUPPLIER -
Manufacturerbased in South San Francisco, CALIFORNIA (USA)
Fostering a culture grounded in our vision, mission and values, CytomX is an Xtraordinary clinical-stage biopharmaceutical company with a unique approach to treating cancer and a team dedicated to make a difference. We call this the CytomX Factor. ...
CytomX - Model CX-072 - PD-L1 - Targeting Probody Therapeutic
CX-072 is a wholly owned PD-L1-targeting Probody therapeutic for the treatment of cancer. Initial clinical data presented at the ASCO and ESMO 2018 Annual Meetings showed that CX-072 demonstrated tolerability and anti-tumor ...
CONTACT SUPPLIER -
Manufacturerbased in Shanghai, CHINA
Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...
Model ES002 - Clinical-Stage Anti-CD39 Antibody
ES002’s dual ATP-adenosine mechanism is a potentially powerful TME regulator and transformative cancer immunotherapy. In preclinical studies ES002 demonstrated significant single agent anti-tumor activity as ...
CONTACT SUPPLIER -
Technologybased in Copenhagen V, DENMARK
Founded in 1999 in Copenhagen, Denmark, we are a dual-listed, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. We are led by an experienced ...
Genmab DuoHexaBody - Model CD37 (GEN3009) - Bispecific IgG1 Antibody
-mediated enhanced hexamerization. In preclinical settings, DuoHexaBody-CD37 has been shown to induce potent in vivo and in vitro anti-tumor ...
CONTACT SUPPLIER -
Software vendorbased in Morrisville, NORTH CAROLINA (USA)
Our mission is to provide comprehensive personalized molecular solutions to inform cancer care. NantOmics, a member of the NantWorks ecosystem of companies, is a leader in molecular diagnostic testing and the first company to employ an integrated ...
-
Manufacturerbased in Nantes, FRANCE
OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Based in Nantes (Head Office) and Paris, OSE Immunotherapeutics ...
OSE - Model BI 765063 (OSE-172) - Tumor Microenvironment (TME)
closely linked to tumor activity and responsiveness to T-cell-targeted ...
CONTACT SUPPLIER -
Manufacturerbased in Utrecht, NETHERLANDS
At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...
-
Manufacturerbased in Cambridge, MASSACHUSETTS (USA)
At Rubius Therapeutics, we are ushering in a new era in cellular medicine—an era in which we aim to transform the treatment of cancer and autoimmune diseases. Built upon the discoveries of Professors Harvey Lodish and Hidde Ploegh of the Whitehead ...
Model RTX-224 - Allogeneic Cellular Therapy
to activate and expand NK cells. It is expected to produce a broad and potent anti-tumor T cell response, an innate immune response and have anti-tumor activity in those ...
CONTACT SUPPLIER -
Manufacturerbased in Bellinzona, SWITZERLAND
We develop live biotherapeutics with multiple human and animal health indications due to adaptive modulation of the gut ecosystem. We are a Swiss microbiome biotherapeutics company, a spin-off from the Institute for Research in Biomedicine (IRB) in ...
ApyraMed - Model MV-002 - Cancer Immunotherapy with Immune Checkpoint Inhibitors (ICIs)
Cancer immunotherapy has therapeutic efficacy in a limited number of patients. Cancer immunotherapy with immune checkpoint inhibitors (ICIs) increases anti-tumor immunity by blocking molecules that suppress ...
CONTACT SUPPLIER -
Manufacturerbased in South San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
Model SENTI-301 - Multi-Armed Allogeneic CAR-NK Cell Therapy for HCC
The product profile of SENTI-301 has the potential to promote expansion and persistence of NK cells, and activate and recruit the body’s own immune cells into the solid tumor microenvironment for ...
CONTACT SUPPLIER -
Manufacturerbased in Planegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Pelabresib - Model CPI-0610 - Investigational Selective Small-Molecule
Pelabresib (CPI-0610) is an investigational selective small-molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain (BET) proteins to decrease the ...
CONTACT SUPPLIER -
Manufacturerbased in County of New Castle, DELAWARE (USA)
MedGenome Inc. is a global leader in personalized medicine with unique genomic solutions in immuno-oncology, diabetes, ophthalmology, cardiology and other rare diseases. Founded in 2013, MedGenome currently has a Next Generation Sequencing (NGS) ...
OncoPeptTUME - Tumor Microenvironment Analysis
. OncoPeptTUME provides a critical assessment of the inflammatory microenvironment that modulates T-cell infiltration and its anti-tumor activities to enable better prediction of treatment response and ...
CONTACT SUPPLIER -
Technologybased in Cambridge, MASSACHUSETTS (USA)
We are a cell therapy company that combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. Vor, the Norse goddess of wisdom, was known as the careful one. ...
VOR - Model VOR33 (CD33) - Hematopoietic Cells
VOR33 is our lead eHSC product candidate designed to replace the standard of care in transplant settings. Once the VOR33 cells have engrafted, we believe that patients can be treated with anti-CD33 therapies, such as Mylotarg or VCAR33, with limited ...
CONTACT SUPPLIER -
Manufacturerbased in New York, NEW YORK (USA)
ENB is developing platform oncology molecules to unlock the full therapeutic potential of immune-based cancer therapies. We are developing small molecules that turn off a common “switch” that activates critical pro-cancer components of the TME: the ...
ENB - Model ENB003 - Potential Synergy with Multiple Immuno-oncology Platforms
ETBR on the luminal surface of tumor blood vessels, creates a barrier to transendothelial migration and homing of T-cells from the vessel to the tumor by downregulating ICAM-1 (an adhesion molecule). ETBRI blockers ...
CONTACT SUPPLIER -
Manufacturerbased in Philadelphia, PENNSYLVANIA (USA)
Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...
Adaptimmune - Model ADP-A2M4CD8 Spear - T-Cell Therapy Pipeline
the engineered TCR that targets MAGE-A4. Preclinical data indicate that co-expression of CD8α may broaden the immune response against solid tumors and increase anti-tumor activity by ...
CONTACT SUPPLIER -
Manufacturerbased in Palo Alto, CALIFORNIA (USA)
BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity. To ...
Model BBP-954 - Gpx4 Inhibitor for Multiple Tumors
designed to target glutathione peroxidase 4 (GPX4) with the hope of providing an effective new therapy for patients with difficult-to-treat tumors. Our approach has demonstrated monotherapy activity, reducing ...
CONTACT SUPPLIER -
Manufacturerbased in Tuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
ACTengine - Next-generation Enhancement Strategies
Immatics’ latest proprietary ACTengine® manufacturing processes are designed to generate cell product candidates within a short manufacturing window and deliver highly proliferative T cells, with the capability to infiltrate the ...
CONTACT SUPPLIER -
Technologybased in Pennington, NEW JERSEY (USA)
OncoSec is a late-stage biotechnology company developing immunotherapy cancer treatments using our plasmid DNA delivery platform. Through our proprietary technology, we are working to deliver safe and effective cancer treatments that can provide ...
OncoSec - Model TAVO - Tavokinogene Telseplasmid + Electroporation (EP) Gene Delivery Technology
We are developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer. We have built a deep clinical pipeline utilizing our primary technology, TAVO™ (tavokinogene telseplasmid) ...
CONTACT SUPPLIER
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you